News

News Archive

Health leaders reveal ten most important medicines in NHS history Health leaders reveal ten most important medicines in NHS history

Antipsychotics, breast cancer drug, oral contraceptives and MMR vaccine make the top ten

Sygnature Discovery announces ambitious expansion plan with addition of Alderley Park facility Sygnature Discovery announces ambitious expansion plan with addition of Alderley Park facility

Sygnature Discovery, a leading independent provider of integrated drug discovery and pre-clinical services and expertise, has today announced the next stage in its ambitious expansion plans with the addition of a new facility located at Alderley Park in Cheshire.

Potential New Class of Drugs May Reduce Cardiovascular Risk by Targeting Gut Microbes Potential New Class of Drugs May Reduce Cardiovascular Risk by Targeting Gut Microbes

The non-antibiotic compounds, tested in animal models, prevented production of gut byproduct linked to heart attack and stroke in humans

The Current issue of “The view from here” is concerned with Models The Current issue of “The view from here” is concerned with Models

The topic of this month’s newsletter from Drug Discovery Today is “Models”

Novel oral therapies could transform the standard-of-care for Diabetic Macular Edema (DME) and lead to prophylactic treatment Novel oral therapies could transform the standard-of-care for Diabetic Macular Edema (DME) and lead to prophylactic treatment

The current standard-of-care for millions of patients across the world with diabetic macular edema (DME) relies on invasive intravitreal injections or implants, both of which are associated with serious risks and side effects. An oral DME treatment could not only provide a less intrusive and safer choice but could also pave the way for prophylactic treatment.

Is Mesoblast’s acute Graft versus Host Disease product poised to fulfil the promise of mesenchymal stem cells? Is Mesoblast’s acute Graft versus Host Disease product poised to fulfil the promise of mesenchymal stem cells?

The therapeutic use of mesenchymal stem cells or MSCs was first investigated in humans in 1995, generating a great deal of early enthusiasm about their promise as easily manufactured allogeneic cellular medicines. Since 1995, MSCs have become one of the most clinically studied experimental cell therapy platforms in the world. After more than 20 years of MSC clinical research, which has not yet resulted in an FDA-approved therapy, many people have questioned whether they can fulfil their therapeutic promise.